BG103674A - Полиморфна форма на зополрестат монохидрат - Google Patents

Полиморфна форма на зополрестат монохидрат

Info

Publication number
BG103674A
BG103674A BG103674A BG10367499A BG103674A BG 103674 A BG103674 A BG 103674A BG 103674 A BG103674 A BG 103674A BG 10367499 A BG10367499 A BG 10367499A BG 103674 A BG103674 A BG 103674A
Authority
BG
Bulgaria
Prior art keywords
zopolrestatmonohydrate
methods
relates
forms
polymorphous form
Prior art date
Application number
BG103674A
Other languages
English (en)
Inventor
John Lambert
Timothy Norris
Original Assignee
Pfizer Products Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc. filed Critical Pfizer Products Inc.
Publication of BG103674A publication Critical patent/BG103674A/bg

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
  • Steroid Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Изобретението се отнася до зополрестатмонохидрат,до негови полиморфни форми и до методи за получаването на зополрестатмонохидрат, на негови полиморфни форми и на безводен зополрестат. Изобретението се отнася също до състави, съдържащи зополрестатмонохидрат, и до методи както за неговото използване, така и за използването на състави на негова базаза лечение на диабетични усложнения като катаракти, етинопатия или невропатия, а също и за снижаване нивото на липидите на пикочната киселина в кръвта.
BG103674A 1998-08-21 1999-08-20 Полиморфна форма на зополрестат монохидрат BG103674A (bg)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US9747498P 1998-08-21 1998-08-21

Publications (1)

Publication Number Publication Date
BG103674A true BG103674A (bg) 2000-03-31

Family

ID=22263562

Family Applications (1)

Application Number Title Priority Date Filing Date
BG103674A BG103674A (bg) 1998-08-21 1999-08-20 Полиморфна форма на зополрестат монохидрат

Country Status (31)

Country Link
US (1) US6159976A (bg)
EP (1) EP0982306A3 (bg)
JP (1) JP2000072769A (bg)
KR (1) KR20000017411A (bg)
CN (1) CN1245804A (bg)
AP (1) AP9901662A0 (bg)
AU (1) AU4453299A (bg)
BG (1) BG103674A (bg)
BR (1) BR9903873A (bg)
CA (1) CA2280590A1 (bg)
EA (1) EA199900675A3 (bg)
EE (1) EE9900385A (bg)
GT (1) GT199900137A (bg)
HR (1) HRP990259A2 (bg)
HU (1) HUP9902783A3 (bg)
ID (1) ID23307A (bg)
IL (1) IL131419A0 (bg)
IS (1) IS5155A (bg)
MA (1) MA26678A1 (bg)
NO (1) NO994027L (bg)
NZ (1) NZ337363A (bg)
OA (1) OA11150A (bg)
PA (1) PA8480601A1 (bg)
PE (1) PE20000993A1 (bg)
PL (1) PL335016A1 (bg)
SG (1) SG83147A1 (bg)
TN (1) TNSN99159A1 (bg)
TR (1) TR199901996A2 (bg)
UY (1) UY25668A1 (bg)
YU (1) YU39899A (bg)
ZA (1) ZA995297B (bg)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3597650T3 (da) 2010-07-16 2022-11-21 Univ Columbia Aldosereduktasehæmmere og anvendelser deraf
US8916563B2 (en) 2010-07-16 2014-12-23 The Trustees Of Columbia University In The City Of New York Aldose reductase inhibitors and uses thereof
US20140228319A1 (en) * 2013-02-13 2014-08-14 Banavara L. Mylari Water soluble salts of aldose reductase inhibitors for treatment of diabetic complications
NZ748506A (en) 2016-06-21 2025-07-25 Univ Columbia Aldose reductase inhibitors and methods of use thereof
IL272246B1 (en) 2017-07-28 2025-09-01 Applied Therapeutics Inc History of 2-(4-oxo/thioketone/azo-3-((substituted)benzo[d]thiazol-2-yl)methyl)- 3,4-dihydrothieno[3,4-d]pyridazin-1-yl)acetic acid for use as an aldose reductase inhibitor for the treatment of galactosemia or prevention of galactosemia-related complications
SG11202110590PA (en) 2019-04-01 2021-10-28 Applied Therapeutics Inc Inhibitors of aldose reductase
AU2020268368A1 (en) 2019-05-07 2022-01-06 Ucl Business Ltd Treatment and detection of inherited neuropathies and associated disorders
WO2021202523A1 (en) 2020-03-31 2021-10-07 Applied Therapeutics, Inc. Aldose reductase inhibitors for the treatment of acute respiratory distress syndrome, acute lung inflammation/injury, cardiac injury and anti-viral therapy
JP2023524504A (ja) 2020-05-01 2023-06-12 アプライド セラピューティクス， インコーポレイテッド ソルビトールデヒドロゲナーゼ欠乏症を処置するためのアルドースレダクターゼ阻害剤
EP4211136B1 (en) * 2020-09-08 2025-08-20 Assia Chemical Industries Ltd. Solid state forms of at-001 and process for preparation thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4748280A (en) * 1985-11-07 1988-05-31 Pfizer Inc. Certain chlorination process for preparing 2-chloro-1,1,1-(C1 -C6)
US4939140A (en) * 1985-11-07 1990-07-03 Pfizer Inc. Heterocyclic oxophthalazinyl acetic acids
JPH0676391B2 (ja) * 1987-06-09 1994-09-28 フアイザー・インコーポレイテツド ベンゾチアゾール等の複素環側鎖を有するオキソフタラジニル酢酸類の製造方法
US4868301A (en) * 1987-06-09 1989-09-19 Pfizer Inc. Processes and intermediates for the preparation of oxophthalazinyl acetic acids having benzothiazole or other heterocyclic side chains
US4904782A (en) * 1988-02-29 1990-02-27 Pfizer Inc. Process for the production of phthalazineacetic acid ester derivatives and a novel intermediate
US4954629A (en) * 1989-05-11 1990-09-04 Pfizer Inc. Process and intermediates for the preparation of oxophthalazinyl acetic acids and analogs thereof
WO1992003432A1 (en) * 1990-08-28 1992-03-05 Pfizer Inc. 3-(5-trifluoromethylbenzothiazol-2-ylmethyl)-4-oxo-3h-phythalazin-1-ylacetic acid monohydrate
US5391551A (en) * 1993-05-10 1995-02-21 Pfizer Inc. Method of lowering blood lipid levels
US6127367A (en) * 1996-02-29 2000-10-03 Pfizer, Inc. Method of reducing tissue damage associated with non-cardiac ischemia

Also Published As

Publication number Publication date
SG83147A1 (en) 2001-09-18
ZA995297B (en) 2001-02-19
HUP9902783A2 (hu) 2000-12-28
PE20000993A1 (es) 2000-10-04
EP0982306A2 (en) 2000-03-01
PL335016A1 (en) 2000-02-28
KR20000017411A (ko) 2000-03-25
NZ337363A (en) 2001-01-26
AU4453299A (en) 2000-03-09
ID23307A (id) 2000-04-05
CN1245804A (zh) 2000-03-01
BR9903873A (pt) 2000-09-19
EP0982306A3 (en) 2000-07-05
GT199900137A (es) 2001-02-09
NO994027L (no) 2000-02-22
JP2000072769A (ja) 2000-03-07
UY25668A1 (es) 2001-08-27
TR199901996A2 (xx) 2000-03-21
EA199900675A2 (ru) 2000-02-28
AP9901662A0 (en) 1999-09-30
HRP990259A2 (en) 2000-06-30
YU39899A (sh) 2002-12-10
OA11150A (en) 2003-04-16
IS5155A (is) 2000-02-22
CA2280590A1 (en) 2000-02-21
EE9900385A (et) 2000-04-17
US6159976A (en) 2000-12-12
HUP9902783A3 (en) 2001-01-29
EA199900675A3 (ru) 2000-06-26
TNSN99159A1 (fr) 2005-11-10
IL131419A0 (en) 2001-01-28
PA8480601A1 (es) 2000-09-29
HU9902783D0 (en) 1999-10-28
NO994027D0 (no) 1999-08-20
MA26678A1 (fr) 2004-12-20

Similar Documents

Publication Publication Date Title
WO2002014252A3 (en) Compositions containing hypoglycemically active stilbenoids
FI962799A0 (fi) Nukleiinihappoja sisältävä valmiste, sen valmistus ja käyttö
WO2002013811A3 (en) Compositions containing hypoglycemically active stilbenoids
CA2331395A1 (en) Fatty acid analogues for the treatment of diabetes
BE2015C026I2 (en) 2-phenyl-1-[-(2-aminoethoxy)-benzyl -indole in combination with estrogens
BR0110084A (pt) Composições e métodos para melhorar saúde vascular
WO2003000200A3 (en) β-2'-OR 3'-HALONUCLEOSIDES
MXPA02011632A (es) Inhibidores de 11-beta-hidroxiesteroide deshidrogenasa tipo 1.
MXPA04004842A (es) Inhibidores de 11-(-hidroxiesteroide deshidrogenasa de tipo 1.
MXPA04004837A (es) Inhibidores de 11-??-hidroxiesteroide deshidrogenasa de tipo 1.
IL161154A0 (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
NO954320L (no) Lyosfærer omfattende gonadotropin
BG103674A (bg) Полиморфна форма на зополрестат монохидрат
EP1077218A3 (en) Peptido-mimetic compounds containing RGD sequence useful as integrin inhibitors
RS44204A (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
ATE188869T1 (de) Stabilisiertes sonnenschutzmittel
RS44304A (en) Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1
MXPA02007903A (es) Uso de acido 2-metil-tiazolidina-2, 4-dicarboxilico (2-mtdc) y/o sales fisiologicamente compatibles para tratar y/o prevenir canceres.
EP1121932A4 (en) MEDICINE FOR EYE DISEASES
WO2004050123A3 (en) Concentrated liquid valdecoxib composition
WO1999048851A3 (en) Processes for preparing intermediates
WO2001051489A3 (en) Methods for lowering uric acid levels
WO2000015797A3 (en) Compositions and methods for the treatment of immune related diseases
EP0393636A3 (en) Liquid crystal composition and liquid crystal display using said composition
MD1473G2 (ro) Remediu antiherpetic